TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Vigil Neuroscience Inc ( (VIGL) ) is now available.
On August 4, 2025, Vigil Neuroscience Inc‘s stockholders approved a merger agreement where each share of common stock was converted into a right to receive $8.00 per share and a contingent value right (CVR). The merger resulted in the delisting of Vigil’s common stock from Nasdaq and significant leadership changes, with the resignation of key executives and board members. The merger positions Vigil as a wholly-owned subsidiary of the parent company, impacting its market presence and operations.
The most recent analyst rating on (VIGL) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Vigil Neuroscience Inc stock, see the VIGL Stock Forecast page.
Spark’s Take on VIGL Stock
According to Spark, TipRanks’ AI Analyst, VIGL is a Underperform.
Vigil Neuroscience Inc’s stock score is primarily affected by its weak financial performance, characterized by no revenue generation and negative cash flows. The technical analysis shows some short-term positive momentum, but valuation concerns and the overbought condition suggest caution. The lack of earnings call and corporate events data means these factors did not influence the score.
To see Spark’s full report on VIGL stock, click here.
More about Vigil Neuroscience Inc
Vigil Neuroscience Inc operates in the biotechnology industry, focusing on developing therapies for neurodegenerative diseases. The company’s primary products or services include clinical candidates aimed at treating neurological conditions.
Average Trading Volume: 1,566,473
Technical Sentiment Signal: Buy
Current Market Cap: $383.9M
See more data about VIGL stock on TipRanks’ Stock Analysis page.